Benchmark Reiterates Buy on Harvard Bioscience, Maintains $4 Price Target

Benchmark analyst Kenneth Bruce reiterates Harvard Bioscience (NASDAQ:HBIO) with a Buy and maintains $4 price target.

Benchmark analyst Kenneth Bruce reiterates Harvard Bioscience (NASDAQ:HBIO) with a Buy and maintains $4 price target.

Total
0
Shares
Related Posts